Chih-Chun Chang
Affiliations: | 2017-2019 | National Tsing Hua University, Hsinchu City, Taiwan, ROC |
Google:
"Chih-Chun Chang"
BETA: Related publications
See more...
Publications
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
Wang LH, Chang CC, Cheng CY, et al. (2022) MCRS1 Expression Regulates Tumor Activity and Affects Survival Probability of Patients with Gastric Cancer. Diagnostics (Basel, Switzerland). 12 |
Huang CP, Liu LC, Chang CC, et al. (2021) Intratumoral xenogeneic tissue-specific cell immunotherapy inhibits tumor growth by increasing antitumor immunity in murine triple negative breast and pancreatic tumor models. Cancer Letters |
Song JS, Chang CC, Wu CH, et al. (2021) A highly selective and potent CXCR4 antagonist for hepatocellular carcinoma treatment. Proceedings of the National Academy of Sciences of the United States of America. 118 |
Chang CC, Dinh TK, Lee YA, et al. (2020) Nanoparticle Delivery of MnO2 and Anti-angiogenic Therapy to Overcome Hypoxia-Driven Tumor Escape and Suppress Hepatocellular Carcinoma. Acs Applied Materials & Interfaces |
Huang KW, Hsu FF, Qiu JT, et al. (2020) Highly efficient and tumor-selective nanoparticles for dual-targeted immunogene therapy against cancer. Science Advances. 6: eaax5032 |
Sung YC, Jin PR, Chu LA, et al. (2019) Delivery of nitric oxide with a nanocarrier promotes tumour vessel normalization and potentiates anti-cancer therapies. Nature Nanotechnology |
Sung YC, Liu YC, Chao PH, et al. (2018) Combined delivery of sorafenib and a MEK inhibitor using CXCR4-targeted nanoparticles reduces hepatic fibrosis and prevents tumor development. Theranostics. 8: 894-905 |
Chen Y, Liu YC, Sung YC, et al. (2017) Overcoming sorafenib evasion in hepatocellular carcinoma using CXCR4-targeted nanoparticles to co-deliver MEK-inhibitors. Scientific Reports. 7: 44123 |
Gao DY, Lin TT, Sung YC, et al. (2015) CXCR4-targeted lipid-coated PLGA nanoparticles deliver sorafenib and overcome acquired drug resistance in liver cancer. Biomaterials. 67: 194-203 |